Daniel A. Heller
Founder at Lime Therapeutics, Inc.
Profile
Daniel A.
Heller is the Chief Scientific Officer and founder of Goldilocks Therapeutics, Inc. founded in 2018.
Dr. Heller is also the founder of Lime Therapeutics, Inc.
Daniel A. Heller active positions
| Companies | Position | Start |
|---|---|---|
Lime Therapeutics, Inc.
 Lime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lime Therapeutics is a biotechnology company that focuses on developing breakthrough lipid-targeting therapeutics using their novel drug discovery platform, LipidSense. The company is based in New York, NY. The company is a spinout company that is developing new technology invented at Memorial Sloan Kettering Cancer Center. Lime Therapeutics is using their breakthrough LipidSense platform to hunt for novel targets and create new drugs that modulate aberrant lipid metabolism in many forms of cancer, metabolic diseases, and neurodegenerative disorders. The company was founded by Shardule Shah, Prakrit Jena, and Daniel A. Heller. Shardule Shah has been the CEO since incorporation. | Founder | - |
Former positions of Daniel A. Heller
| Companies | Position | End |
|---|---|---|
Goldilocks Therapeutics, Inc.
 Goldilocks Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Goldilocks Therapeutics, Inc. engages in the development of drug delivery technology for kidney tubules. It offers treatment for acute kidney injury (AKI), polycystic kidney disease (PKD), and other under-treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs). The company was founded by Arthur J. Klausner, Daniel A. Heller, and Edgar A. Jaimes in 2018 and is headquartered in Bedford, NY. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Goldilocks Therapeutics, Inc.
Goldilocks Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Goldilocks Therapeutics, Inc. engages in the development of drug delivery technology for kidney tubules. It offers treatment for acute kidney injury (AKI), polycystic kidney disease (PKD), and other under-treated kidney conditions by leveraging the Company’s proprietary mesoscale nanoparticles (MNPs). The company was founded by Arthur J. Klausner, Daniel A. Heller, and Edgar A. Jaimes in 2018 and is headquartered in Bedford, NY. | Commercial Services |
Lime Therapeutics, Inc.
Lime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lime Therapeutics is a biotechnology company that focuses on developing breakthrough lipid-targeting therapeutics using their novel drug discovery platform, LipidSense. The company is based in New York, NY. The company is a spinout company that is developing new technology invented at Memorial Sloan Kettering Cancer Center. Lime Therapeutics is using their breakthrough LipidSense platform to hunt for novel targets and create new drugs that modulate aberrant lipid metabolism in many forms of cancer, metabolic diseases, and neurodegenerative disorders. The company was founded by Shardule Shah, Prakrit Jena, and Daniel A. Heller. Shardule Shah has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Daniel A. Heller
